Figure 3. OGT2115 improved glycemic control in STZ-induced diabetic mice. (A) The structure of OGT2115. (B) The animal experiment procedure. (C) Random blood glucose levels after experimental administration of OGT2115. (D) Body weight after administration. (E) Food intake after administration. (F) Four weeks after OGT2115 administration, the blood glucose concentration during an intraperitoneal glucose tolerance test (IPGTT). *p<0.05, **p<0.01 compared to STZ group, n=10. (G) AUC of the IPGTT curves. (H) Plasma insulin levels before and 30 min after glucose injection during the IPGTT, *p<0.05, **p<0.01, ***p<0.001 as indicated, n=10.